NEW YORK--(BUSINESS WIRE)--NeoStem, Inc. (AMEX:NBS), the first company to specialize in the collection, processing and storage of stem cells from healthy adults for personal use in times of critical medical need, announced that Murphy Analytics (MA), a fee-based equity research firm, has issued a research report update that projects a 12-month target share price of $9.25 citing the Company’s improved financial position, strong senior management team and its recent listing on the American Stock Exchange.
